Global Central Nervous System Disorders Pipeline Database

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Global Central Nervous System Disorders Pipeline Database Update 2016

Dublin, Oct. 17, 2016 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Central Nervous System Disorders Pipeline Database - 2016 Update" report to their offering. Central Nervous System Disorders Pipeline Highlights Database - 2016 Update, provides most up-to-date information on key pipeline products in the global Central Nervous System (CNS) disorders Drug market. It covers emerging therapies for CNS indications in active clinical development stages including early and late stage clinical trials. Key indications covered in this database include Multiple Sclerosis, Depression, Alzheimer's disease, Parkinson's disease, ADHD, Schizophrenia, Epilepsy, Migraine, and Huntington's disease. The pipeline data is presented in an excel dashboard with filtering options. The pipeline data presented in this database helps executives for tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing and out-licensing deals. By Indication: The database presents pipeline by CNS indications. Key indications covered in this database include Multiple Sclerosis, Depression, Alzheimer's disease, Parkinson's disease, ADHD, Schizophrenia, Epilepsy, Migraine, and Huntington's disease. By Clinical Trial Stages: The database provides CNS disorders pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage. By Drug Mechanism Classes: The database provides CNS disorders pipeline products by their dominant drug mechanism class. This helps executives categorize products based on their drug class and also assess the strengths and weaknesses of compounds. By Company: The database provides CNS disorders pipeline products by the company. SUMMARY: - CNS disorders Pipeline by Indication - CNS disorders Pipeline by Clinical Trial Phase - CNS disorders Pipeline by Drug Mechanism Classes - CNS disorders Pipeline by Company For more information about this report visit http://www.researchandmarkets.com/research/68...al_nervous

CONTACT: Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Related Topics: Central Nervous System Drugs

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Current Market Sentiment on HealthEquity Shares: A Closer Look

Updated Category News Views 113

Understanding HealthEquity's Short Interest Dynamics HealthEquity Inc (NYSE: HQY) has seen a significant decrease in its short percent of float, which recently dropped by 11.68%. As of the last report, the company had approximately 5.26 million shares sold short, representing 7.03% of its regular shares available for trading. This situation also highlights an average...

Continue Reading
Investors Update: Class Action Against Bumble Inc. Soon

Updated Category News Views 104

Update on Class Action Lawsuit Against Bumble Inc. (BMBL) The Law Offices of Frank R. Cruz are reminding investors about an upcoming significant deadline concerning a class action lawsuit against Bumble Inc. This lawsuit affects investors who acquired BMBL securities during the designated Class Period. Understanding the Class Action Lawsuit The class action was initiated...

Continue Reading
Analysis of Williams-Sonoma's Recent Surge and Current Changes

Updated Category News Views 293

Understanding Williams-Sonoma's Recent Stock Movements This week has seen an impressive rise of nearly 30% in shares of Williams-Sonoma, Inc. (NYSE: WSM), but recent trading indicates a slight pullback. Investors are reacting to two key factors: the natural tendency to take profits and the decision of some buyers to exit losing positions as market conditions evolve. The...

Continue Reading
Understanding the Arconic Corporation Class Action Update

Updated Category News Views 139

Overview of the Class Action Lawsuit Against Arconic Corporation Levi & Korsinsky, LLP has recently announced a class action regarding Arconic Corporation (ARNC). This situation affects investors who may have been impacted by alleged securities fraud. The firm aims to represent those who traded Arconic shares during a specified period and seeks to recover losses resulting...

Continue Reading
Cambrex Partners with Lilly to Enhance Biotech Innovations

Updated Category News Views 220

Cambrex's Strategic Collaboration with Eli Lilly Cambrex, a key player in the global contract development and manufacturing organization (CDMO) sector, has announced an exciting new partnership with Eli Lilly and Company to enhance support for biotech collaborators. Through this agreement, Cambrex aims to provide accelerated access to essential clinical development...

Continue Reading